GHRP-2 Effectively Stimulates Growth Hormone Release Even in Critically Ill Patients

In critically ill patients with blunted GH secretion, GHRP-2 maintained the ability to stimulate GH release, offering a potential strategy to combat the protein wasting and hormonal disruption of critical illness.

Van den Berghe, G et al.·Clinical endocrinology·1996·Strong EvidenceRCT
RPEP-00391RCTStrong Evidence1996RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
RCT
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

GHRP-2 maintained GH-releasing efficacy in critically ill patients despite blunted responses to GHRH, suggesting a preserved alternative pathway for GH stimulation.

Key Numbers

How They Did This

Clinical study testing pituitary GH responses to GHRH, GHRP-2, and TRH in critically ill patients, comparing to expected normal responses.

Why This Research Matters

Muscle wasting in ICU patients significantly impacts recovery. If GHRP-2 can stimulate GH release when normal pathways are suppressed, it could help preserve muscle mass during critical illness.

The Bigger Picture

This study contributed to understanding how the GH axis is disrupted in critical illness and identified GHRP-2 as a potential intervention to combat ICU-related muscle wasting and metabolic dysfunction.

What This Study Doesn't Tell Us

Clinical study in critically ill patients — a heterogeneous population. Sample size and specific response magnitudes not detailed in abstract. Functional outcomes not assessed.

Questions This Raises

  • ?Could GHRP-2 treatment reduce muscle wasting and improve outcomes in ICU patients?
  • ?Should GH secretagogues be part of standard ICU endocrine management?

Trust & Context

Key Stat:
GHRP-2 works in critical illness Unlike GHRH, GHRP-2 maintained its GH-releasing ability even when the GH axis was suppressed by critical illness
Evidence Grade:
Moderate clinical evidence from a study in critically ill patients. Demonstrates preserved GHRP-2 responsiveness but lacks outcome data.
Study Age:
Published in 1996, this study highlighted GHRP-2's potential in critical care, an application area still under investigation.
Original Title:
Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
Published In:
Clinical endocrinology, 45(3), 341-51 (1996)
Database ID:
RPEP-00391

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Why is GH important in critical illness?

Growth hormone promotes protein synthesis and muscle preservation. In critical illness, GH secretion drops dramatically, contributing to severe muscle wasting that delays recovery and increases complications.

Why does GHRP-2 still work when GHRH doesn't?

GHRP-2 and GHRH work through completely different receptors and pathways. In critical illness, the GHRH pathway is suppressed, but the GHRP/ghrelin receptor pathway remains functional, allowing GHRP-2 to bypass the blockade.

Read More on RethinkPeptides

Cite This Study

RPEP-00391·https://rethinkpeptides.com/research/RPEP-00391

APA

Van den Berghe, G; de Zegher, F; Bowers, C Y; Wouters, P; Muller, P; Soetens, F; Vlasselaers, D; Schetz, M; Verwaest, C; Lauwers, P; Bouillon, R. (1996). Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.. Clinical endocrinology, 45(3), 341-51.

MLA

Van den Berghe, G, et al. "Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.." Clinical endocrinology, 1996.

RethinkPeptides

RethinkPeptides Research Database. "Pituitary responsiveness to GH-releasing hormone, GH-releasi..." RPEP-00391. Retrieved from https://rethinkpeptides.com/research/van-1996-pituitary-responsiveness-to-ghreleasing

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.